Compare ADMA Biologics Inc (ADMA) vs Moody's Corporation (MCO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Moody's Corporation — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Moody's Corporation trades at $485.38 (market cap $87.42B). The key difference: Moody's Corporation is far larger — about 41× ADMA Biologics Inc's market cap, and Moody's Corporation pays a 0.82% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | MCO | |
|---|---|---|
Market Cap | $2.13B | $87.42B |
Sector | Health | Financials |
52-Week High | $20.38 | $539.61 |
52-Week Low | $7.60 | $412.23 |
Enterprise Value | $2.20B | $93.23B |
Dividend Yield | — | 0.82% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
Moody's Corporation (MCO) trades at $500.49, up 2.03% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 31.69% net margins and consistent earnings beats, while trading at premium valuations (P/E 35.78). Recent AI integration announcements and dividend payments highlight strategic growth initiatives.
MCO presents a compelling growth story with strong profitability and analyst support (56% buy ratings, $542 consensus target), though elevated valuations and RSI overbought signals warrant caution. Key risks include competitive pressures and market sensitivity to credit cycles, but the company's market position and AI strategy support long-term upside potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Moody's Corporation
Moody's, along with S&P Ratings, is a leading provider of credit ratings on fixed income securities. Moody's ratings segment, known as Moody's Investors Service or MIS, includes corporates, structured finance, financial institutions, and public finance ratings. MIS represents a majority of the firm's revenue and profits. Moody's other segment is Moody's Analytics and consists of Research, Data, and Analytics or RD&A and Enterprise Risk Solutions or ERS. RD&A's products include credit research, quantitative credit scores, economic research, business intelligence, know your customer (KYC) tools, commercial real estate data and analytical tools, and training services. ERS includes risk management software solutions to financial institutions.
Read more on MCO →
